About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSEĀ® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
View Top Employees from Catalyst Pharmaceuticals, Inc.Looking for a particular Catalyst Pharmaceuticals, Inc. employee's phone or email?
The Catalyst Pharmaceuticals, Inc. annual revenue was $153.7 million in 2024.
Steve Miller is the COO of Catalyst Pharmaceuticals, Inc..
118 people are employed at Catalyst Pharmaceuticals, Inc..
Catalyst Pharmaceuticals, Inc. is based in Coral Gables, Florida.
The NAICS codes for Catalyst Pharmaceuticals, Inc. are [3254, 541714, 54, 32, 325, 5417, 54171, 541].
The SIC codes for Catalyst Pharmaceuticals, Inc. are [873, 283, 2834, 87, 28].